Healthy VolunteersPhase 1NCT07267221
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
A Phase 1 study testing DWJ1622 and DWC202313, DWC202314 in people with Healthy Volunteers, run by Daewoong Pharmaceutical Co. LTD. at 1 site in South Korea.
Trial summary
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions. Read more about this study
- Who is it for?
- Ages 19 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers
- What is being tested?
- DWJ1622 and DWC202313, DWC202314
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Dec 2025to 30 May 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Over 19 year old
- Healthy adult volunteers
Who cannot join
- with a history of mental disorder
- For female volunteers, those who are suspected of being pregnant or lactating
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
H Plus YANGJI Hospital
Seoul, Gwanak-gu, 08779
Bae, 8218778875
About this study
Official title: An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "DWJ1622" and Co-administration of "DWC202313" and "DWC202314" in Healthy Volunteers
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.
Read the detailed description
This is an open-label, randomized, oral, single-dose, 2-sequence, 2-period, crossover Phase 1 study to evaluate the pharmacokinetics and safety profiles of DWJ1622, DWC202313, and DWC202314 in healthy volunteers under fed conditions. Subjects will be randomized to receive either DWJ1622 or the co-administration of DWC202313 and DWC202314 in different sequences across two study periods with an appropriate washout period.
The primary pharmacokinetic endpoints include the maximum observed plasma concentration (Cmax) and the area under the plasma concentration-time curve to the last measurable concentration (AUClast) of each study drug. Secondary endpoints include the area under the plasma concentration-time curve extrapolated to infinity (AUCinf), the ratio of AUClast to AUCinf (AUClast/AUCinf), the time to reach maximum plasma concentration (Tmax), and the terminal elimination half-life (t1/2). Safety will be evaluated based on adverse events and clinical laboratory tests.
- Conditions
- Healthy Volunteers
- Being tested
- DWJ1622, DWC202313, DWC202314
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DWJ1622Drug
DWJ1622 (single oral dose) is administered in accordance with the study protocol.
DWC202313, DWC202314Drug
DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.
| Study group | Role | What they receive |
|---|---|---|
| DWJ1622 | Experimental | Not described Receives: Drug: DWJ1622; Drug: DWC202313, DWC202314 |
| DWC202313, DWC202314 | Experimental | Not described Receives: Drug: DWJ1622; Drug: DWC202313, DWC202314 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax
Cmax of DWJ1622 and DWC202313, DWC202314
Measured: At pre-dose (0 hours), and post-dose 1 to 72 hours.
AUClast
AUClast of DWJ1622 and DWC202313, DWC202314
Measured: Time Frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Secondary outcomes (3)
AUCinf
AUCinf of DWJ1622 and DWC202313, DWC202314
Measured: At pre-dose (0 hours), and post-dose 1 to 72 hours.
AUClast/AUCinf
AUClast/AUCinf of DWJ1622 and DWC202313, DWC202314
Measured: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Tmax
Tmax of DWJ1622 and DWC202313, DWC202314
Measured: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2025
- Study start1 Dec 2025 (estimated)
- Primary completion30 Jan 2026 (estimated)
- Study completion30 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- More trials run by Daewoong Pharmaceutical Co. LTD.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07267221
- Sponsor's protocol ID
- DW_DWJ1622103
- Status last verified
- Dec 2025
- First submitted
- 16 Nov 2025
- Last updated
- 5 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "DWJ1622" and Co-administration of "DWC202313" and "DWC202314" in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT07267221
- Acronym / sponsor ID
- DW_DWJ1622103
- Conditions
- Healthy Volunteers
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry (pharma, biotech, devices)
- Study start
- 1 Dec 2025 (estimated)
- Primary completion
- 30 Jan 2026 (estimated)
- Study completion
- 30 May 2026 (estimated)
- First posted
- 5 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.
Detailed description
This is an open-label, randomized, oral, single-dose, 2-sequence, 2-period, crossover Phase 1 study to evaluate the pharmacokinetics and safety profiles of DWJ1622, DWC202313, and DWC202314 in healthy volunteers under fed conditions. Subjects will be randomized to receive either DWJ1622 or the co-administration of DWC202313 and DWC202314 in different sequences across two study periods with an appropriate washout period.
The primary pharmacokinetic endpoints include the maximum observed plasma concentration (Cmax) and the area under the plasma concentration-time curve to the last measurable concentration (AUClast) of each study drug. Secondary endpoints include the area under the plasma concentration-time curve extrapolated to infinity (AUCinf), the ratio of AUClast to AUCinf (AUClast/AUCinf), the time to reach maximum plasma concentration (Tmax), and the terminal elimination half-life (t1/2). Safety will be evaluated based on adverse events and clinical laboratory tests.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| DWJ1622 | Experimental | Drug: DWJ1622, Drug: DWC202313, DWC202314 |
| DWC202313, DWC202314 | Experimental | Drug: DWJ1622, Drug: DWC202313, DWC202314 |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Over 19 year old
- Healthy adult volunteers
Key exclusion criteria (2 listed)
- with a history of mental disorder
- For female volunteers, those who are suspected of being pregnant or lactating
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DWJ1622DWJ1622 (single oral dose) is administered in accordance with the study protocol. | Drug | DWC202313, DWC202314, DWJ1622 |
| DWC202313, DWC202314DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol. | Drug | DWC202313, DWC202314, DWJ1622 |
Primary outcome
Cmax
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Cmax of DWJ1622 and DWC202313, DWC202314
AUClast
Time frame: Time Frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
AUClast of DWJ1622 and DWC202313, DWC202314
3 secondary outcomes
AUCinf
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
AUClast/AUCinf
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Tmax
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2025.
Related trials for Healthy Volunteers
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Not yet recruitingObservational study
Screening Protocol
Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DWJ1622 and DWC202313, DWC202314 in people with Healthy Volunteers, run by Daewoong Pharmaceutical Co. LTD. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact SHIN (825508858, hbshin028@daewoong.co.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax (time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2025.